20:07 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Nohla adds $11M to series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised an additional $11 million on June 11 in the second close of a series B financing, bringing the round’s total to $56 million. New investors...
16:42 , Jul 6, 2018 |  BC Week In Review  |  Company News

Athenex Announces Two China Deals Plus $100M Raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy July 2 that also saw the biotech raise $100 million in equity and debt. The company said it is forming a...
23:18 , Jul 2, 2018 |  BC Extra  |  Company News

Athenex announces two China deals plus $100M raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy Monday that also saw the biotech raise $100 million in equity and debt. The company said it is forming a JV,...
02:30 , May 18, 2018 |  BC Week In Review  |  Financial News

Arch leads Nohla's $45M series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised $45 million on May 15 in a series B round led by existing investor Arch Venture Partners. Also participating were new investors Fidelity Management and...
20:54 , May 15, 2018 |  BC Extra  |  Financial News

Arch leads Nohla's $45M series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised $45 million in a series B round led by existing investor Arch Venture Partners. Also participating were new investors Fidelity Management and Celgene Corp. (NASDAQ:CELG)...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led the...
17:50 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; bioinformatics screen A yeast-based method coupled with bioinformatics could help identify tumor antigens that stimulate orphan TCRs for use in cancer T cell therapies and vaccines. The method involves screening TCRs derived from...
20:00 , Feb 16, 2018 |  BC Week In Review  |  Company News

Astellas acquires Universal Cells

Astellas Pharma Inc. (Tokyo:4503) said it has acquired Universal Cells Inc. (Seattle, Wash.) for up to $102.5 million in an upfront payment and milestones. Astellas will gain Universal Cells' technology to develop universal pluripotent stem cells...
19:31 , Jan 24, 2018 |  BC Innovations  |  Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the HLA-DQ8...
19:55 , Jan 11, 2018 |  BC Innovations  |  Translation in Brief

Quality over quantity

A study in Nature has challenged the assumption that pancreatic cancers are poorly immunogenic by linking long-term survival in patients to the quality, not the quantity, of neoantigens in expressed their tumors, highlighting the antigens’...